New study aims to catch cancer recurrences before they show on scans

NCT ID NCT07469709

Recruiting now Knowledge-focused Sponsor: Fondazione del Piemonte per l'Oncologia Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is looking for better ways to predict who might develop or have a return of certain cancers, including breast, colon, ovarian, melanoma, and lung cancer. Researchers will collect blood samples from 850 participants to study genetic and other biological markers. The goal is to catch cancer or its return earlier, before it can be seen on standard tests.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to better ways to predict who is at risk for certain cancers and detect recurrences earlier, potentially improving outcomes.
What could go wrong: This is an observational study, not a treatment trial. It may not directly benefit participants, and the findings may take years to translate into clinical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm colonic neoplasm colorectal cancer melanoma non-small cell lung carcinoma ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER COLO-RECTAL CANCER MELANOMA (SKIN CANCER) NON-SMALL CELL LUNG CANCER (MESH TERM: CARCINOMA, NON-SMALL-CELL LUNG) OVARIAN CANCER

Contacts and locations

Locations

Fondazione del Piemonte per l'Oncologia-IRCCS Candiolo
RECRUITING

Candiolo, Turin, 10060, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.